Compare IPI & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPI | FDMT |
|---|---|---|
| Founded | 2000 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 499.4M | 449.6M |
| IPO Year | 2007 | 2019 |
| Metric | IPI | FDMT |
|---|---|---|
| Price | $34.19 | $8.67 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $25.00 | ★ $31.71 |
| AVG Volume (30 Days) | 165.8K | ★ 665.3K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 105.14 | 18.79 |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $298,328,000.00 | $85,209,000.00 |
| Revenue This Year | $5.01 | N/A |
| Revenue Next Year | N/A | $70.28 |
| P/E Ratio | $64.04 | ★ N/A |
| Revenue Growth | 17.13 | ★ 230194.60 |
| 52 Week Low | $22.55 | $3.68 |
| 52 Week High | $50.34 | $12.34 |
| Indicator | IPI | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 37.99 | 46.65 |
| Support Level | $33.33 | $8.39 |
| Resistance Level | $35.78 | $10.40 |
| Average True Range (ATR) | 1.50 | 0.74 |
| MACD | -0.25 | -0.01 |
| Stochastic Oscillator | 12.83 | 23.32 |
Intrepid Potash Inc produces and sells potash and potash byproducts in three main product segments: Potash, Trio, and Oilfield Solutions. The Potash segment produces and sells potash to the agricultural industry as a fertilizer input, the industrial market as a component of oil and gas drilling fluid, and the animal feed market as a nutrient supplement. The Trio segment produces and sells specialty fertilizer that consists of potassium, sulfate, and magnesium and is mined from langbeinite ore. The oilfield solutions segment offers water, high-speed potassium chloride mixing services, saltwater disposal services, and trucking services. The vast majority of revenue is generated in the United States, where the firm's production facilities are located.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).